These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

18 related articles for article (PubMed ID: 30914563)

  • 1. XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI.
    Suzuki K; Takaharu K; Muto Y; Ichida K; Fukui T; Takayama Y; Tsujinaka S; Sasaki J; Horie H; Kawamura YJ; Konishi F; Rikiyama T
    Mol Clin Oncol; 2014 Sep; 2(5):827-832. PubMed ID: 25054053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study on prediction of early adverse events by CapeOX therapy in patients with colorectal cancer.
    Kumihashi Y; Kasai Y; Akagawa T; Yuasa Y; Ishikura H; Sato Y
    J Med Invest; 2024; 71(1.2):141-147. PubMed ID: 38735710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
    Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
    BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Two Cases of Rectal Cancer Resected Curatively after Chemotherapy with CapeOX plus Bmab].
    Chiku T; Sano W; Hashiba T; Togawa Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1647-9. PubMed ID: 26805125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of recurrent rectal cancer successfully treated for a long period with capecitabine plus oxaliplatin and bevacizumab therapy].
    Iwata N; Ishikawa T; Takahashi H; Baba H; Masuda D; Okazaki S; Matsuyama T; Ishiguro M; Kobayashi H; Iida S; Uetake H; Sugihara K
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2008-10. PubMed ID: 24393995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [XELIRI plus Bmab Therapy as a Secondary Treatment for Recurrent Colorectal Cancer with Long-Term Survival].
    Yukimoto R; Fukunaga M; Konishi K; Matsuno Y; Nakai S; Takiguchi N; Honda S; Saito A; Takeoka T; Okada K; Ota H; Yokoyama S; Kobayashi K
    Gan To Kagaku Ryoho; 2019 Feb; 46(2):369-371. PubMed ID: 30914563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of cecum colon cancer with lymph node metastasis successfully treated with XELOX plus bevacizumab].
    Ito S; Ichikawa R; Kure K; Honjo K; Aoki J; Okazawa Y; Mizukoshi K; Ro H; Kawai M; Takehara K; Okubo H; Ishiyama S; Sugimoto K; Komiyama H; Takahashi M; Yaginuma Y; Kojima Y; Goto M; Tomiki Y; Sakamoto K
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1425-8. PubMed ID: 25434448
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.